Giudice, Linda C; As-sanie, Sawsan; Ferreira, Juan C. Arjona; Becker, Christian M; Abrão, Maurício Simões 
; Lessey, Bruce A; Brown, Eric; Dynowski, Krzysztof; Wilk, Krzysztof; Li, Yulan
Subjects: CO-TERAPIA, GONADOTROFINAS, ENDOMETRIOSE, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUDICE, Linda C et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, v. 399, n. 10343, p. 2267-2279, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00622-5. Acesso em: 01 nov. 2024.APA
Giudice, L. C., As-sanie, S., Ferreira, J. C. A., Becker, C. M., Abrão, M. S., Lessey, B. A., et al. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, 399( 10343), 2267-2279. doi:10.1016/S0140-6736(22)00622-5NLM
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5Vancouver
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5
